摘要
[目的]探讨多西紫杉醇联合奥沙利铂治疗中晚期食管癌的疗效及毒副反应。[方法]32例经病理证实中晚期食管癌患者,多西紫杉醇60~75mg/m2,静脉滴注,d1,70岁以上老年患者35~40mg/m2,静脉滴注,d1、8;奥沙利铂100mg/m2,静脉滴注,d2。21d为1个周期。[结果]32例患者中,CR1例（3.13%）,PR12例（37.50%）,SD9例（28.13%）,PD10例（31.25%）,总有效率为40.63%,临床获益率为68.75%。其中初治患者有效率44.44%,复治患者有效率35.71%。主要毒副反应为骨髓抑制和神经感觉异常,非血液学毒性反应较轻,无化疗相关死亡。[结论]多西紫杉醇联合奥沙利铂治疗中晚期食管癌疗效较好,且毒副反应可耐受。
[Purpose] To investigate the response and toxicity of docetaxel（TXT） combined with oxali- platin（OXA） in the treatment of advanced esophageal cancer. [Methods] Thirty-two cases with advanced esophageal cancer pathologically proved were enrolled. All patients received docetaxel 60～ 75mg/m2, iv gtt, d1; except patients over 70 years old received docetaxel 35～40mg/m2, iv gtt, d1,8. Oxaliplatin 100mg/m2, iv gtt, d2. Twenty-one days as a cycle. [Results] Of 32 cases, 1 case（3.13%） was CR; 12 （37.50%）, PR; 9 （28.13%）, SD; and 10 （31.25%）, PD. The overall response rate was 40.63%, clinical benefit rate was 68.75%. The response rate in initial treatment group and in recurrence group was 44.44% and 35.71%, respectively. The main toxicity was myelosuppression and nerve toxicity,non-hematic toxicity was mild, no treatment-related death occurred. [Conclusion]Do-cetaxel combined with oxaliplatin is effective and tolerable for advanced esophageal cancer.
出处
《肿瘤学杂志》
CAS
2010年第10期802-804,共3页
Journal of Chinese Oncology
